MOAT ROSS (Group VP & Rilonacept GM) sold 16.4% of their position (2.37K shares) of KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC on the open market
Open‑market sale worth $115.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 4/8/2026ACC: 0001857177-26-000004
Officer· Group VP & Rilonacept GM
Since Apr 2021
-3.14K
Net shares
Net seller
$152.9K
Total sold
1
Open market trades
0B · 1S
4
Total transactions
2.48K acquired · 5.62K disposed
Non-Derivative Transactions3
Class A Ordinary Share
Direct
Shares
−2.37K
Price / share
$48.58
Trade value
$114.99K
% of position
16.4%
4/6/2026
14.40K→12.03K
Class A Ordinary Share
Direct
Shares
+2.48K
Price / share
—
Trade value
—
% of position
20.6%
4/7/2026
12.03K→14.51K
Class A Ordinary Share
Direct
Shares
−774.00
Price / share
$48.94
Trade value
$37.88K
% of position
5.3%
4/7/2026
14.51K→13.73K
Total
Net shares
−664.00
Net value
-$152.87K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Share Direct | 4/6/2026 | S · Sale | −2.37K | $48.58 | $114.99K | 16.4% | 14.40K | 12.03K |
| Class A Ordinary Share Direct | 4/7/2026 | M · Option Exercise | +2.48K | — | — | 20.6% | 12.03K | 14.51K |
| Class A Ordinary Share Direct | 4/7/2026 | F · Tax Withholding | −774.00 | $48.94 | $37.88K | 5.3% | 14.51K | 13.73K |
| Total | −664.00 | -$152.87K | ||||||
Derivative Transactions1
Restricted Share Unit
Direct
Converts to
Class A Ordinary Share
2.48K shares
Shares
−2.48K
Strike price
Held after
0.00
Exercisable
—
4/7/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Share Unit Direct | Class A Ordinary Share2.48K shares | 4/7/2026 | M · Option Exercise | −2.48K | — | 0.00 |